Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
Abbott Laboratories said Thursday its executive vice president of pharmaceutical products is retiring.
The company said Olivier Bohuon will “shortly announce his plans to accept another opportunity” in a report filed with the Securities and Exchange Commission. The North-Chicago based company named Richard A. Gonzalez the interim vice president.
Boston Scientific Corp. said on Wednesday it completed the refinancing of its debt due to mature in 2011 with new $3-billion bank facilities. It also arranged a $1-billion three-year term loan which will be used to prepay its $900 million term loan due to Abbott Laboratories Inc. in April 2011.
Reuters | Depomed Inc. said U.S. health regulators accepted the company’s
marketing application for its experimental pain drug, triggering a $10
million milestone payment from its licensee and sending its shares up 12
percent.
From Dividend.com | Health care products maker Abbott Laboratories saw its rating cut on Monday by analysts at Goldman Sachs. The firm lowered its rating on ABT to “Neutral” from “Buy,” but maintained its $69 price target on the stock. That target represents a more than 48% upside to Abbott’s Friday closing price of $46.53.
Get the full story: dividend.com.
